拜瑪林製藥 BMRN 深 滬
等待開盤 08-21 09:30:00 美东时间
67.68
-1.650
-2.38%
華盛通- 最 高68.75
- 今 開68.106
- 成交量 127.56万股
- 最 低 67.565
- 昨 收 69.33
- 總市值 131.01亿
- 52周最高 70.98
- 市盈率 靜 37.50
- 換手率 0.66%
- 52周最低 49.2592
- 委 比 27.05%
- 總股本 1.94亿
- 歷史最高 151.75
- 量 比 0.64
- 振 幅 1.71%
- 歷史最低 23.735
- 每 手 1
- 風險率 3.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday agreed to purchase Alesta Therapeutics, strategically securing its primary clinical-stage asset, ALE1. The acquisition aims to significantly bolster BioMarin’s portfolio with a potential first-in-class oral treatment for a rare genetic bone disor...
08-19 01:37
BioMarin to gain hypophosphatasia drug under Alesta buyout
BioMarin Pharmaceutical (BMRN) on Tuesday announced an agreement to acquire Alesta Therapeutics to gain access to the Dutch biotech’s lead asset, ALE1, which targets a rare disorder called hypophospha...
08-18 20:52
BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1. Alesta plans to spin out all non-ALE1 assets prior to the close of the transaction, which has been approve...
08-18 20:31
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $105 to $111.
08-17 21:22
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
美股盘后 | 康耐视小升1.99%，Brookfield基础设施小升1.95%
康耐视小升1.99%；Brookfield基础设施小升1.95%；Gen Digital小升1.93%
08-08 06:10
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.
08-07 19:04
财报速睇 | 拜玛林制药2026财年Q2营收9.90亿美元，同比增长19.9%；归母净利润0.45亿美元，同比下滑81.4%
华盛资讯8月7日讯，拜玛林制药公布2026财年Q2业绩，公司Q2营收9.90亿美元，同比增长19.9%，归母净利润0.45亿美元，同比下滑81.4%。
08-07 09:24
